EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

H. pylori infection induces WEE1 to promote drug resistance in gastric adenocarcinoma

Md Obaidul Islam, Krishnapriya Thangaretnam, Jialun Lv, Zhenzhen Zhang, Mohammed Soutto, Shoumin Zhu, Wael El-Rifai, Oliver Gene McDonald, Yan Guo, Zheng Chen

Acta Pharmaceutica Sinica B · 2026-11

DOI: 10.1016/j.apsb.2026.11.018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-11. Verfasst von Md Obaidul Islam und 9 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Mark Foundation for Cancer Research, DeGregorio Family Foundation, Florida Department of Health.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastric cancer (GC) remains a leading cause of cancer-related mortality, with frequent resistance to therapy. This study identifies a non-canonical role for the nuclear kinase WEE1 in GC progression and drug resistance, particularly in the context of Helicobacter pylori ( H. pylori ) infection. WEE1 is aberrantly overexpressed and mislocalized to the cytoplasm in GC cells. Gene set enrichment analysis (GSEA) of over 2000 patient samples consistently shows that WEE1-high tumors are enriched in MYC and E2F target genes. Mechanistically, WEE1 promotes E2F1 activation by phosphorylating RB, thereby upregulating MYC transcription. In turn, MYC enhances WEE1 and E2F1 expressions, establishing a feedforward oncogenic circuit. H. pylori infection induces this WEE1–E2F1–MYC axis, linking microbial pathogenesis to transcriptional reprogramming and tumor progression. WEE1 inhibition using MK1775 suppresses MYC signaling, downregulates anti-apoptotic genes such as BCL2 and BCL2L1 , and sensitizes GC cells to DNA-damaging agents. A high-throughput screen of 892 FDA-approved drugs identifies Afatinib as a potent synergistic partner of MK1775. Combination therapy enhances anti-tumor activity in vitro , in patient-derived xenografts, and organoids. These findings highlight a novel microbial-driven signaling axis and support WEE1 as an actionable therapeutic target in MYC-driven, therapy-resistant gastric cancer.

Förderung

  • The Mark Foundation for Cancer Research
  • DeGregorio Family Foundation
  • Florida Department of Health
  • Gastric Cancer Foundation
  • National Institutes of Health

Zitieren

APA

Islam, M. O., Thangaretnam, K., Lv, J., Zhang, Z., Soutto, M., Zhu, S., El-Rifai, W., McDonald, O. G., Guo, Y., & Chen, Z. (2026). H. pylori infection induces WEE1 to promote drug resistance in gastric adenocarcinoma. Acta Pharmaceutica Sinica B. https://doi.org/10.1016/j.apsb.2026.11.018

Vancouver

Islam MO, Thangaretnam K, Lv J, Zhang Z, Soutto M, Zhu S, et al. H. pylori infection induces WEE1 to promote drug resistance in gastric adenocarcinoma. Acta Pharmaceutica Sinica B. 2026. doi:10.1016/j.apsb.2026.11.018

BibTeX
@article{Islam2026,
  author = {Islam, Md Obaidul and Thangaretnam, Krishnapriya and Lv, Jialun and Zhang, Zhenzhen and Soutto, Mohammed and Zhu, Shoumin and El-Rifai, Wael and McDonald, Oliver Gene and Guo, Yan and Chen, Zheng},
  title = {H. pylori infection induces WEE1 to promote drug resistance in gastric adenocarcinoma},
  journal = {Acta Pharmaceutica Sinica B},
  year = {2026},
  doi = {10.1016/j.apsb.2026.11.018}
}
Kostenlos starten →